Protective	protective	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
misoprostol	misoprostol	O	O	OTHERS	I
on	on	O	O	O	O
indomethacin	indomethacin	CHEMICALS	O	OTHERS	I
induced	induced	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
in	in	O	O	O	O
elderly	elderly	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
To	to	O	O	O	O
evaluate	evaluate	O	O	O	O
the	the	O	O	O	O
possible	possible	O	O	O	O
protective	protective	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
misoprostol	misoprostol	O	O	OTHERS	I
on	on	O	O	O	O
renal	renal	O	O	O	O
function	function	O	O	O	O
in	in	O	O	O	O
hospitalized	hospitalized	O	O	O	O
elderly	elderly	O	O	O	O
patients	patients	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
indomethacin	indomethacin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
Forty-five	forty-five	O	O	O	O
hospitalized	hospitalized	O	O	O	O
elderly	elderly	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
>	>	O	O	O	O
65	65	O	O	O	O
years	years	O	O	O	O
old	old	O	O	O	O
)	)	O	O	O	O
who	who	O	O	O	O
required	required	O	O	O	O
therapy	therapy	O	O	O	O
with	with	O	O	O	O
nonsteroidal	nonsteroidal	O	O	O	O
antiinflammatory	antiinflammatory	O	O	O	O
drugs	drugs	O	O	O	O
(	(	O	O	O	O
NSAID	nsaid	O	O	OTHERS	I
)	)	O	O	O	O
were	were	O	O	O	O
randomly	randomly	O	O	O	O
assigned	assigned	O	O	O	O
to	to	O	O	O	O
receive	receive	O	O	O	O
either	either	O	O	O	O
indomethacin	indomethacin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
150	150	O	O	O	O
mg/day	mg/day	O	O	O	O
(	(	O	O	O	O
Group	group	O	O	O	O
A	a	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
or	or	O	O	O	O
indomethacin	indomethacin	CHEMICALS	O	OTHERS	I
150	150	O	O	O	O
mg/day	mg/day	O	O	O	O
plus	plus	O	O	O	O
misoprostol	misoprostol	O	O	OTHERS	I
at	at	O	O	O	O
0.6	0.6	O	O	O	O
mg/day	mg/day	O	O	O	O
(	(	O	O	O	O
Group	group	O	O	O	O
B	b	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Laboratory	laboratory	O	O	O	O
variables	variables	O	O	O	O
of	of	O	O	O	O
renal	renal	O	O	O	O
function	function	O	O	O	O
[	[	O	O	O	O
serum	serum	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
blood	blood	CHEMICALS	O	OTHERS	I
urea	urea	CHEMICALS	O	OTHERS	I
nitrogen	nitrogen	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
BUN	bun	O	O	OTHERS	I
)	)	O	O	O	O
and	and	O	O	O	O
electrolytes	electrolytes	O	O	O	O
]	]	O	O	O	O
were	were	O	O	O	O
evaluated	evaluated	O	O	O	O
before	before	O	O	O	O
initiation	initiation	O	O	O	O
of	of	O	O	O	O
therapy	therapy	O	O	O	O
and	and	O	O	O	O
every	every	O	O	O	O
2	2	O	O	O	O
days	days	O	O	O	O
,	,	O	O	O	O
until	until	O	O	O	O
termination	termination	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
(	(	O	O	O	O
a	a	O	O	O	O
period	period	O	O	O	O
of	of	O	O	O	O
at	at	O	O	O	O
least	least	O	O	O	O
6	6	O	O	O	O
days	days	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Response	response	O	O	O	O
to	to	O	O	O	O
treatment	treatment	O	O	O	O
was	was	O	O	O	O
estimated	estimated	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
visual	visual	O	O	O	O
analog	analog	O	O	O	O
scale	scale	O	O	O	O
for	for	O	O	O	O
severity	severity	O	O	O	O
of	of	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Forty-two	forty-two	O	O	O	O
patients	patients	O	O	O	O
completed	completed	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
,	,	O	O	O	O
22	22	O	O	O	O
in	in	O	O	O	O
Group	group	O	O	O	O
A	a	O	O	O	O
and	and	O	O	O	O
20	20	O	O	O	O
in	in	O	O	O	O
Group	group	O	O	O	O
B.	b.	O	O	O	O
BUN	bun	O	O	OTHERS	I
and	and	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
increased	increased	O	O	O	O
by	by	O	O	O	O
>	>	O	O	O	O
50	50	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
baseline	baseline	O	O	O	O
levels	levels	O	O	O	O
in	in	O	O	O	O
54	54	O	O	O	O
and	and	O	O	O	O
45	45	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
Group	group	O	O	O	O
A	a	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
,	,	O	O	O	O
compared	compared	O	O	O	O
to	to	O	O	O	O
only	only	O	O	O	O
20	20	O	O	O	O
and	and	O	O	O	O
10	10	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
Group	group	O	O	O	O
B	b	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
p	p	O	O	OTHERS	I
<	<	O	O	O	O
0.05	0.05	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Potassium	potassium	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
K	k	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
increment	increment	O	O	O	O
of	of	O	O	O	O
0.6	0.6	O	O	O	O
mEq/l	meq/l	O	O	O	O
or	or	O	O	O	O
more	more	O	O	O	O
was	was	O	O	O	O
observed	observed	O	O	O	O
in	in	O	O	O	O
50	50	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
Group	group	O	O	O	O
A	a	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
in	in	O	O	O	O
only	only	O	O	O	O
15	15	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
Group	group	O	O	O	O
B	b	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
p	p	O	O	OTHERS	I
<	<	O	O	O	O
0.05	0.05	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
mean	mean	O	O	O	O
increments	increments	O	O	O	O
in	in	O	O	O	O
BUN	bun	O	O	OTHERS	I
,	,	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
K	k	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
reduced	reduced	O	O	O	O
by	by	O	O	O	O
63	63	O	O	O	O
,	,	O	O	O	O
80	80	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
42	42	O	O	O	O
%	%	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
Group	group	O	O	O	O
B	b	O	O	O	O
patients	patients	O	O	O	O
compared	compared	O	O	O	O
to	to	O	O	O	O
Group	group	O	O	O	O
A.	a.	O	O	O	O
Response	response	O	O	O	O
to	to	O	O	O	O
treatment	treatment	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
differ	differ	O	O	O	O
significantly	significantly	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
2	2	O	O	O	O
groups	groups	O	O	O	O
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
Hospitalized	hospitalized	O	O	O	O
elderly	elderly	O	O	O	O
patients	patients	O	O	O	O
are	are	O	O	O	O
at	at	O	O	O	O
risk	risk	O	O	O	O
for	for	O	O	O	O
developing	developing	O	O	O	O
indomethacin	indomethacin	CHEMICALS	O	OTHERS	I
related	related	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Addition	addition	O	O	O	O
of	of	O	O	O	O
misoprostol	misoprostol	O	O	OTHERS	I
can	can	O	O	O	O
minimize	minimize	O	O	O	O
this	this	O	O	O	O
renal	renal	O	O	OTHERS	I
impairment	impairment	O	O	OTHERS	I
without	without	O	O	O	O
affecting	affecting	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
control	control	O	O	O	O
.	.	O	O	O	O

